Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak Durin… (NCT05954962) | Clinical Trial Compass
CompletedPhase 4
Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.
Spain150 participantsStarted 2023-12-23
Plain-language summary
This study aims to investigate if the use of oral micronized natural progesterone is not inferior to the use of subcutaneous antagonist in preventing LH peak in controlled ovarian stimulation.
Who can participate
Age range18 Years – 33 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Eligibility for the oocyte donation program at Instituto Bernabeu.
* Age between 18 and 33 years
* BMI \>18 and \<30
* Overall antral follicle count \>8
* Presence of both ovaries
* Ability to participate and comply with the study protocol
* Oral and written comprehension of Spanish
* Having given written consent
Exclusion Criteria:
* Endometriosis at any stage
* Any ovarian tumor whether benign or malignant
* Concurrent participation in another study
* Malabsorptive syndromes that may alter the efficacy of Seidigestan ® such as bariatric surgery, ulcerative colitis or Crohn's disease
* Irregular periods
* Hypogonadotropic hypogonadism
* Having received in the previous two months treatment with ovulation stimulators
* Having previously participated in the present study
What they're measuring
1
MII oocytes
Timeframe: Egg collection day (between 8 and 14 days after starting of ovarian stimulation)